ZYVERSA THERAPEUTICS, INC. Increase (Decrease) in Derivative Liabilities
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Increase (Decrease) in Derivative Liabilities of $186.40 thousand for the 11-month period ending 2022-12-12, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2023-03-31
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2022-09-30 was $0.00.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 11 month |
|---|---|---|---|---|
| 2022-12-12 | $186.40K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$76.59K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | -$76.59K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |